Eribulin in "field practice': an overview of the Italian experience

被引：5

作者：

Barni, Sandro ^{[1
]}

机构：

[1] Azienda Osped, Med Oncol, Treviglio, BG, Italy

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 15期

关键词：

breast cancer; case study; erbulin mesylate; BREAST-CANCER; PATIENT;

D O I：

10.2217/fon.15.157

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although the diagnostic and therapeutic advantages achieved in recent years have led to a decrease in the incidence of breast cancer-related deaths, metastatic breast cancer is still associated with an overall poor prognosis.

引用

页码：1 / 2

页数：2

共 11 条

[1] Long response to eribulin in breast cancer: a case report [J].

Borgonovo, Karen ;

Petrelli, Fausto ;

Cabiddu, Mary ;

Ghilardi, Mara ;

Coinu, Andrea ;

Seghezzi, Silvia ;

Barni, Sandro .

FUTURE ONCOLOGY, 2015, 11 (15) :3-8

[2] Benefit of eribulin in a patient with HER2+ breast cancer who progressed after trastuzumab and lapatinib: a case report [J].

Casanova, Claudia ;

Verlicchi, Alberto ;

Mazza, Valentina ;

Dazzi, Claudio .

FUTURE ONCOLOGY, 2015, 11 (15) :9-15

[3] Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study [J].

Cortes, Javier ;

O'Shaughnessy, Joyce ;

Loesch, David ;

Blum, Joanne L. ;

Vahdat, Linda T. ;

Petrakova, Katarina ;

Chollet, Philippe ;

Manikas, Alexey ;

Dieras, Veronique ;

Delozier, Thierry ;

Vladimirov, Vladimir ;

Cardoso, Fatima ;

Koh, Han ;

Bougnoux, Philippe ;

Dutcus, Corina E. ;

Seegobin, Seth ;

Mir, Denis ;

Meneses, Nicole ;

Wanders, Jantien ;

Twelves, Chris .

LANCET, 2011, 377 (9769) :914-923

[4] Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer [J].

Dawood, Shaheenah ;

Broglio, Kristine ;

Gonzalez-Angulo, Ana M. ;

Buzdar, Aman U. ;

Hortobagyi, Gabriel N. ;

Giordano, Sharon H. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (30) :4891-4898

[5] Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient [J].

Gubbiotti, Marta ;

Pistilli, Barbara ;

Tudini, Marianna ;

Benedetti, Giovanni ;

Galizia, Eva ;

Rusiello, Marco ;

Latini, Luciano .

FUTURE ONCOLOGY, 2015, 11 (15) :17-22

[6] Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient [J].

Iorfida, Monica ;

Mazza, Manuelita .

FUTURE ONCOLOGY, 2015, 11 (15) :23-26

[7] Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report [J].

Leo, Luigi ;

Caputo, Francesca ;

Di Sarno, Antonella ;

Garofano, Tiziana ;

Andreozzi, Francesca ;

Massaro, Maria Grazia ;

Montesarchio, Vincenzo .

FUTURE ONCOLOGY, 2015, 11 (15) :27-30

[8] Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience [J].

Martella, Francesca ;

Bacci, Carlotta ;

Giordano, Clara ;

Montagnani, Francesco ;

Gelain, Elena ;

Rabatti, Loredana ;

Fioretto, Luisa .

FUTURE ONCOLOGY, 2015, 11 (15) :31-36

[9] We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC [J].

Rizzo, Mimma ;

Carteni, Giacomo ;

Pappagallo, Giovanni .

FUTURE ONCOLOGY, 2014, 10 (12) :1893-1896

[10]

Siegel RL, 2020, ANTI-CANCER DRUG, V70, P7, DOI [10.3322/caac.21590, DOI 10.1097/CAD.0000000000000617]

← 1 2 →